Why are long-acting beta-adrenoceptor agonists long-acting?
- PMID: 7912202
- DOI: 10.1183/09031936.94.07030569
Why are long-acting beta-adrenoceptor agonists long-acting?
Abstract
The extended duration of bronchodilation due to formoterol and salmeterol greatly exceeds that of short acting beta 2-adrenoceptor agonists, such as salbutamol or terbutaline. This extended duration and their capacity to "reassert" airway smooth muscle relaxation in vitro despite repeated washing has prompted considerable debate on the underlying mechanism(s). The comparative pharmacology, and molecular modelling of these drugs and of the beta 2-adrenoceptor and its ligand binding core have cast doubt on the exosite/exoceptor model previously proposed to explain the behaviour of salmeterol. We present evidence supporting a unifying hypothesis that the duration of action both of formoterol and salmeterol is determined principally by their physicochemical interactions with membrane lipid bilayers (plasmalemma diffusion microkinetic model), rather than putative distinct exosite/exoceptor binding sites in or near the beta 2-adrenoceptor. This model provides a clearer understanding of the pharmacological profile of these drugs (rate of onset, duration, "reassertion", interaction with hydrophilic and hydrophobic beta 2-adrenoceptor antagonists), and explains why in human airway smooth muscle in vitro a true relaxation-concentration response may not exist for salmeterol.
Similar articles
-
Long acting inhaled beta-adrenoceptor agonists the comparative pharmacology of formoterol and salmeterol.Agents Actions Suppl. 1993;43:253-69. doi: 10.1007/978-3-0348-7324-6_22. Agents Actions Suppl. 1993. PMID: 8103622
-
Extent of salmeterol-mediated reassertion of relaxation in guinea-pig trachea pretreated with aliphatic side chain structural analogues.Br J Pharmacol. 1996 Mar;117(6):1009-15. doi: 10.1111/j.1476-5381.1996.tb16690.x. Br J Pharmacol. 1996. PMID: 8882590 Free PMC article.
-
Pharmacological similarities and differences between beta2-agonists.Respir Med. 2001 Aug;95 Suppl B:S7-11. doi: 10.1053/rmed.2001.1139. Respir Med. 2001. PMID: 11534896 Review.
-
Relaxation kinetics of formoterol and salmeterol in the guinea pig trachea in vitro.Lung. 1996;174(3):159-70. doi: 10.1007/BF00173308. Lung. 1996. PMID: 8830192
-
Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists.Lung. 1996;174(1):1-22. doi: 10.1007/BF00167947. Lung. 1996. PMID: 8746998 Review.
Cited by
-
Current issues with beta2-adrenoceptor agonists: pharmacology and molecular and cellular mechanisms.Clin Rev Allergy Immunol. 2006 Oct-Dec;31(2-3):119-30. doi: 10.1385/CRIAI:31:2:119. Clin Rev Allergy Immunol. 2006. PMID: 17085788 Review.
-
Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes.Can Respir J. 2018 Jun 19;2018:2732017. doi: 10.1155/2018/2732017. eCollection 2018. Can Respir J. 2018. PMID: 30018677 Free PMC article. Review.
-
Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists.Naunyn Schmiedebergs Arch Pharmacol. 2010 Sep;382(3):255-63. doi: 10.1007/s00210-010-0533-6. Epub 2010 Aug 8. Naunyn Schmiedebergs Arch Pharmacol. 2010. PMID: 20694793
-
On the mechanism of the persistent action of salmeterol: what is the current position?Br J Pharmacol. 2009 Sep;158(1):180-2. doi: 10.1111/j.1476-5381.2009.00370.x. Br J Pharmacol. 2009. PMID: 19719780 Free PMC article. Review.
-
Asthma and COPD: A Focus on β-Agonists - Past, Present and Future.Handb Exp Pharmacol. 2024;285:369-451. doi: 10.1007/164_2023_679. Handb Exp Pharmacol. 2024. PMID: 37709918 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
